ENDRA Life Sciences Inc (NDRA) - Total Liabilities

Latest as of March 2026: $1.65 Million USD

Based on the latest financial reports, ENDRA Life Sciences Inc (NDRA) has total liabilities worth $1.65 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

ENDRA Life Sciences Inc - Total Liabilities Trend (2014–2025)

This chart illustrates how ENDRA Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of ENDRA Life Sciences Inc to evaluate short-term liquidity relative to the company's equity base.

ENDRA Life Sciences Inc Competitors by Total Liabilities

The table below lists competitors of ENDRA Life Sciences Inc ranked by their total liabilities.

Company Country Total Liabilities
Visgeneer
TWO:4197
Taiwan NT$135.94 Million
High Arctic Energy Services Inc.
TO:HWO
Canada CA$7.84 Million
Taitron Components Incorporated
NASDAQ:TAIT
USA $2.02 Million
Aumake Ltd
AU:AUK
Australia AU$4.53 Million
Workspace Group PLC
LSE:WKP
UK GBX955.40 Million
Intanwijaya Internasional Tbk
JK:INCI
Indonesia Rp73.38 Billion
SCC Holdings Bhd
KLSE:0158
Malaysia RM5.87 Million
XOX Bhd
KLSE:0165
Malaysia RM188.00 Million

Liability Composition Analysis (2014–2025)

This chart breaks down ENDRA Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of ENDRA Life Sciences Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.64 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.92 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.48 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ENDRA Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ENDRA Life Sciences Inc (2014–2025)

The table below shows the annual total liabilities of ENDRA Life Sciences Inc from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 $1.59 Million -15.77%
2024-12-31 $1.89 Million +72.76%
2023-12-31 $1.10 Million -47.08%
2022-12-31 $2.07 Million -0.99%
2021-12-31 $2.09 Million +31.01%
2020-12-31 $1.60 Million -33.94%
2019-12-31 $2.42 Million +147.86%
2018-12-31 $974.58K +14.90%
2017-12-31 $848.21K -38.74%
2016-12-31 $1.38 Million +485.62%
2015-12-31 $236.42K +142.23%
2014-12-31 $97.60K --

About ENDRA Life Sciences Inc

NASDAQ:NDRA USA Diagnostics & Research
Market Cap
$9.26 Million
Market Cap Rank
#27539 Global
#5615 in USA
Share Price
$5.01
Change (1 day)
+6.82%
52-Week Range
$3.19 - $8.84
All Time High
$10412.50
About

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fa… Read more